

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

Brilliant Violet 785(TM) anti-mouse/rat/human CD27

RRID:AB_2800595

Type: Antibody

Proper Citation

BioLegend Cat# 124241, RRID:AB_2800595

Antibody Information

URL: http://antibodyregistry.org/AB_2800595

Proper Citation: BioLegend Cat# 124241, RRID:AB_2800595

Target Antigen: CD27

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse/rat/human CD27

Description: This monoclonal targets CD27

Target Organism: rat, mouse, human

Clone ID: Clone LG.3A10

Antibody ID: AB_2800595

Vendor: BioLegend

Catalog Number: 124241

Record Creation Time: 20250819T212049+0000

Record Last Update: 20250819T223918+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse/rat/human CD27.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse/rat/human CD27.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wei X, et al. (2025) Immune imprinting blunts omicron pathogenicity fluctuations and highlights the essential role of cellular immunity in SARS-CoV-2 infection. Cell reports, 44(6), 115784.

Galvez-Cancino F, et al. (2025) Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies. Immunity, 58(5), 1236.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer cell, 42(6), 1032.

Jaeger-Ruckstuhl CA, et al. (2024) Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. Immunity, 57(2), 287.

Cohen GS, et al. (2023) Transplantation elicits a clonally diverse CD8+ T cell response that is comprised of potent CD43+ effectors. Cell reports, 42(8), 112993.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. Immunity, 56(1), 207.

van Elsas MJ, et al. (2023) Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for immunotherapy of cancer, 11(3).